In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Missed Opportunities: Why Small Biotech Needs To Plan Ahead For Global Reach

Executive Summary

If small biotech does more to plan ahead for ex-US market requirements, companies and their investors – and crucially patients – will benefit.

You may also be interested in...



Medicare, Alzheimer’s Drugs And The Single Payer Effect

US biopharma stakeholders are getting a taste of how a single payer health care system can shape the fate of a new treatment with Medicare’s national coverage determination for amyloid-directed Alzheimer’s drugs including Biogen/Eisai’s Aduhelm.

Bluebird Bio Decision in Europe Is A Wake-Up Call For Payers and Industry

Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.

UK HTA Body To Conduct More Appraisals, And Faster, Through Proportionate Approach

Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV124998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel